37,000 Shares in Syndax Pharmaceuticals, Inc. $SNDX Purchased by Wesbanco Bank Inc.

Wesbanco Bank Inc. acquired a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 37,000 shares of the company’s stock, valued at approximately $777,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Syndax Pharmaceuticals by 21.2% in the fourth quarter. Vanguard Group Inc. now owns 6,230,334 shares of the company’s stock worth $130,899,000 after acquiring an additional 1,091,717 shares in the last quarter. Torray Investment Partners LLC bought a new stake in Syndax Pharmaceuticals in the fourth quarter worth about $2,055,000. Mirae Asset Global Investments Co. Ltd. raised its position in Syndax Pharmaceuticals by 26.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after acquiring an additional 893 shares in the last quarter. CWM LLC raised its position in Syndax Pharmaceuticals by 50.7% in the fourth quarter. CWM LLC now owns 31,912 shares of the company’s stock worth $670,000 after acquiring an additional 10,737 shares in the last quarter. Finally, Palumbo Wealth Management LLC bought a new stake in Syndax Pharmaceuticals in the fourth quarter worth about $1,079,000.

Syndax Pharmaceuticals Price Performance

NASDAQ SNDX opened at $21.49 on Monday. The stock’s 50-day moving average price is $23.06 and its two-hundred day moving average price is $20.54. The company has a current ratio of 5.47, a quick ratio of 5.06 and a debt-to-equity ratio of 8.26. The company has a market cap of $1.90 billion, a PE ratio of -7.70 and a beta of 0.41. Syndax Pharmaceuticals, Inc. has a 1 year low of $8.58 and a 1 year high of $25.59.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.11. The firm had revenue of $64.86 million for the quarter, compared to the consensus estimate of $69.76 million. Syndax Pharmaceuticals had a negative return on equity of 256.65% and a negative net margin of 111.88%.The business’s revenue for the quarter was up 224.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.98) EPS. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -1.67 EPS for the current year.

Analyst Ratings Changes

SNDX has been the topic of several research reports. Mizuho dropped their price target on shares of Syndax Pharmaceuticals from $45.00 to $43.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target (down from $48.00) on shares of Syndax Pharmaceuticals in a research report on Monday, March 30th. Citigroup boosted their price target on shares of Syndax Pharmaceuticals from $51.00 to $57.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. The Goldman Sachs Group boosted their price target on shares of Syndax Pharmaceuticals from $28.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Finally, JPMorgan Chase & Co. boosted their price target on shares of Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an “overweight” rating in a research report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Syndax Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $42.64.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.